Search
Keros Therapeutics Inc
KROSAdd to Watchlist
10.650USD
+0.240+2.31%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
210.15MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Keros Therapeutics Inc is 7.25, ranking 307 out of 389 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 35.00 and a low of 16.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
21.833
Target Price
+105.01%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Keros Therapeutics Inc
KROS
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Keros Therapeutics Inc's expected revenue for the next quarter?
Keros Therapeutics Inc's expected revenue is 807.14K.
What is Keros Therapeutics Inc's price target?
Analysts forecast that Keros Therapeutics Inc's price target is USD 22.50, with the highest forecast at USD 35.00 and the lowest forecast at USD 16.00.
How have Keros Therapeutics IncKROS's recent earnings per share performed?
The market expectation was USD -1.21, while Keros Therapeutics IncKROS's earnings per share (EPS) for the previous quarter was USD -0.87. EPS for the next quarter is expected at USD -1.34.
What is the analyst rating for Keros Therapeutics Inc?
Based on the ratings of Keros Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
